Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

Table 3 Survival per biological response category

Biological (AFP) response	Total n	Overall survival, mo (mean ± SEM)	n of deaths (%)	n alive at study closure (%)
Increase ≥ 25%	16	9.6 ± 1.8	15 (93.7)	1 (6.3)
Stable	2	2	2 (100)	0 (0)
Decrease ≥ 25% without normalization	1	26	1 (100)	0 (0)
Normalization of AFP (< 7 μg/L)	5	Not assessable	0 (0)	5 (100)
AFP remains negative	5	13.8 ± 3.9	4 (80)	1 (20)
Overall	29	14.5 ± 2.1	22 (75.9)	7 (24.1)

Not assessable: Patients were alive at study closure. AFP: Alpha-fetoprotein.